Thalidomide
Top View
- Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs
- BICALUTAMIDE -- Withdrawn Due to Accelerated Deaths
- Appendix B - Product Name Sorted by Applicant
- Thalidomide Metabolism by the CYP2C Subfamily1
- Thalidomide-Celgene-Epar-Product
- Antitumor Effects of Thalidomide Analogs in Human Prostate Cancer Xenografts Implanted in Immunodeficient Mice
- Invited Lecture Presented at the Canadian Society of Pharmacology and Therapeutics Annual Meeting
- The Hitchhiker's Guide to Clinical Pharmacology
- Pharmaceutical Compositions and Dosage Forms of Thalidomide
- FEP 5 Tier Rx Drug Formulary (607) Standard Option
- NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2014
- Thalidomide: the Tragedy of Birth Defects and the Effective Treatment of Disease
- Thalidomide Does Not Interact with P-Glycoprotein
- THALOMID U.S. Prescribing Information
- Early Refill Drug Utilization Review Drugs
- A Randomized Phase II Trial of Thalidomide, an Angiogenesis Inhibitor, in Patients with Androgen-Independent Prostate Cancer1
- 1. NAME of the MEDICINAL PRODUCT <Invented Name> 50 Mg
- Novel Chiral LC Methods for the Enantiomeric Separation of Bicalutamide and Thalidomide on Amylose Based Immobilized CSP